Method for promoting generation of microvesicles containing mitochondria and medical use thereof
Through the combined use of factors that promote mitochondria and extracellular vesicles, the production of mitochondria-rich microvesicles is solved, and the mitochondria production and preservation problem is achieved, and efficient mitochondrial preparation production and therapeutic effects are achieved.
Patent Information
- Application Number
- PCT/CN2023/092873
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-09
- Publication Date
- 2024-11-14
AI Technical Summary
The prior art cannot produce and preserve high-quality mitochondria in large quantities and long-term storage, and the isolated mitochondria are easily damaged, making it difficult to mass produce and preserve purified mitochondrial preparations.
Using combined use of factors that promote mitochondria production and factors that promote extracellular vesicle production, mitochondria-rich microvesicles are generated through cell co-culture. The microvesicle structure protects the mitochondria from being easily damaged, and isolates the extracellular vesicle composition and Coating to achieve stable preservation of mitochondria and continuous production of therapeutic agents.
A simple, large and continuous production of mitochondrial preparations is achieved, so mitochondria are easier to preserve, and the microvesicle structure promotes mitochondria entering damaged cells, improves therapeutic ability, and solves the technical obstacles to the application of purified mitochondrial preparations.
Smart Images

Figure CN2023092873_14112024_PF_FP_ABST
Abstract
Description
Method for promoting the generation of microvesicles with mitochondria and medical use thereof Technical Field
[0001] The present invention relates to the combined use of a factor promoting mitochondrial production and a factor promoting extracellular vesicle production. Furthermore, the present invention relates to a method for causing cells to produce an extracellular vesicle composition rich in mitochondrial microvesicles, an isolated extracellular vesicle composition, a pharmaceutical containing the same, and its uses. Background Art
[0002] Stem cells are undifferentiated mother cells that have the ability to differentiate into cells with different functions and replicate to produce more identical stem cells. Because stem cells have the ability to replicate and differentiate into other cell types, they were considered a potential treatment for diseases, leading to the development of stem cell-based therapies. Stem cell therapy, defined as the use of stem cells to treat a variety of diseases, dates back to bone marrow transplantation in 1968. However, this technique involved the transplantation of hematopoietic stem cells. While different from today's mesenchymal stem cell transplants, it can still be considered the beginning of allogeneic stem cell therapy. After promising results in numerous animal studies, mesenchymal stem cells were gradually used to treat human diseases after 2000. For example, in 2003, bone marrow stem cells were implanted into the left ventricle to repair myocardial tissue. Application to human spinal cord injuries has shown significant improvement in mobility. In stroke treatment, stem cells can reduce acute inflammation and long-term brain degeneration, promoting long-term functional recovery. Studies on brain injuries have demonstrated the ability to alleviate symptoms and improve mobility and long-term memory. Adult stem cells derived from fat have also been shown to be effective in treating neurological diseases. Time and facts have proven that although stem cell therapy is effective, the original differentiation replacement theory has always been inconsistent with the results of experimental research. Therefore, the therapeutic principle of mesenchymal stem cells has never been determined.
[0003] Recent research has confirmed that the therapeutic effects of stem cells stem from substances secreted by stem cells, including mitochondria, which are transferred to damaged cells through channels, gap junctions, microvesicles, and cell fusion. The damaged cells then acquire these exogenous mitochondria, which is the primary reason for the stem cells' therapeutic effects. Numerous papers, such as Paliwal et al. (2018), have also demonstrated that the regenerative capacity of mesenchymal stem cells stems from mitochondrial transport. In the same year, Wang et al. (2018) proposed that mitochondrial transport of stem cells is a novel therapeutic technique for tissue damage.
[0004] Current research has also confirmed that stem cells with superior mitochondrial quality possess greater therapeutic potential. Later research has directly confirmed that whole stem cells are not required for treatment. Injecting isolated mitochondria directly into the lungs can treat lung inflammation and restore fibrotic alveoli. Alternatively, injecting free mitochondria directly into the brain can treat stroke to reduce cerebral infarction size, and multiple system atrophy (MSA) to reduce brain damage and improve behavioral abilities.
[0005] Therefore, delivering healthy mitochondria into damaged cells can promote cell resuscitation, growth, and activation, potentially improving aging and various degenerative diseases caused by mitochondrial damage. However, the biggest technical obstacle to achieving such an effective treatment is the lack of methods for mass-producing mitochondria. Furthermore, isolated mitochondria, upon leaving the intracellular environment, quickly become damaged and die, making them difficult to preserve. Consequently, purified mitochondrial preparations remain difficult to manufacture, mass-produce, and preserve for extended periods.
[0006] Summary of the Invention
[0007] Given that existing technologies cannot mass-produce mitochondria, and even if they are produced, they are difficult to preserve, the innovation of the present invention lies in the simple, large-scale, and continuous mass production of mitochondrial preparations. The mitochondria produced are easier to preserve for a long time. Due to the structure of the vesicles and the components within them, they can not only protect the mitochondria from damage, but also promote the mitochondria to enter damaged cells, thereby enhancing the therapeutic ability, and solving all technical barriers to the practical application of purified mitochondrial preparations at one time.
[0008] To achieve the aforementioned objectives, the present invention provides a method for combining a factor promoting mitochondrial production with a factor promoting extracellular vesicle production, which is used to promote cells having mitochondria to produce microvesicles having mitochondria.
[0009] The use according to the present invention may be for non-therapeutic purposes.
[0010] The present invention utilizes a combination of factors promoting mitochondrial production and extracellular vesicle production to produce large quantities of microvesicles containing mitochondria. These microvesicles facilitate the entry of mitochondria into damaged cells for repair. Furthermore, the collected mitochondria are already encapsulated by microvesicles and protected by small RNA molecules, making them easier to preserve.
[0011] According to the present invention, the cells having mitochondria can produce extracellular vesicles and microvesicles having mitochondria.
[0012] Preferably, the ratio of the factor promoting mitochondrial production to the factor promoting extracellular vesicle production is 1:1 to 1:1000, for example, 1:1 to 1:8, 1:1 to 1:6, 1:1 to 1:4, or 1:100, 1:300, 1:600, or 1:900. More preferably, the ratio of the factor promoting mitochondrial production to the factor promoting extracellular vesicle production is 1:1 to 1:5.
[0013] Preferably, the mitochondrial production-promoting factor can be selected from the group consisting of: heme oxygenase-1 (HO-1), CoPPIX (Co-protoporphyrin IX), hemin, hemin derivatives (e.g., hemin chloride), hemoprotein, broken red blood cells, mitochondrial structure fragments, cell tissue fragments, and 5%-20% oxygen concentration environment culture.
[0014] Preferably, the factor promoting extracellular vesicle production can be selected from the group consisting of ethanol, an EP4 receptor antagonist (e.g., GW627368X), endosomal sorting complex required for transport (ESCRT), ARRDC1 (arrestin domain-containing protein 1), associated protein's tumor suppressor gene 101 (TSG101), and cytochalasin B. The factor promoting extracellular vesicle production can promote the production of microvesicles and exosomes in cells.
[0015] Preferably, the cells having mitochondria are mesenchymal stem cells, hematopoietic stem cells, bone marrow stem cells, liver cells, or other somatic cells. More preferably, the cells having mitochondria are mesenchymal stem cells. Preferably, the mesenchymal stem cells are neonatal mesenchymal stem cells or embryonic stem cells.
[0016] To achieve the aforementioned object, the present invention further provides a method for producing an extracellular vesicle composition enriched in microvesicles having mitochondria, comprising:
[0017] Step (1) preparing cells with mitochondria;
[0018] Step (2) adds a factor promoting mitochondrial production and a factor promoting extracellular vesicle production to the cells having mitochondria and co-cultivates them in a culture medium to obtain an extracellular vesicle composition rich in microvesicles having mitochondria, and the extracellular vesicle composition rich in microvesicles having mitochondria has more than 0.2% of microvesicles having mitochondria based on the total number of extracellular vesicles.
[0019] Preferably, the step (2) comprises:
[0020] Step (2-1) adding a factor promoting mitochondrial production and a factor promoting extracellular vesicle production to the cells having mitochondria in a culture medium for co-culturing; and
[0021] In step (2-2), an extracellular vesicle composition is isolated from the co-culture medium to obtain an extracellular vesicle composition enriched in microvesicles containing mitochondria. The extracellular vesicle composition enriched in microvesicles containing mitochondria contains at least 0.2% of microvesicles containing mitochondria, based on the total number of extracellular vesicles. In other words, the extracellular vesicle composition is obtained by removing cells and culture medium containing mitochondria. In other words, at least 0.2% of the extracellular vesicles are microvesicles containing mitochondria.
[0022] Preferably, the step (2) is to first add a factor promoting mitochondrial production to the cells having mitochondria, and then add a factor promoting extracellular vesicle production to the culture medium for co-culturing, to obtain an extracellular vesicle composition rich in microvesicles having mitochondria, and the extracellular vesicle composition rich in microvesicles having mitochondria has more than 0.2% of microvesicles having mitochondria based on the total number of extracellular vesicles. In another embodiment, the step (2) is to first add a factor promoting extracellular vesicle production to the cells having mitochondria, and then add a factor promoting mitochondria production to the culture medium for co-culturing, to obtain an extracellular vesicle composition rich in microvesicles having mitochondria, and the extracellular vesicle composition rich in microvesicles having mitochondria has more than 0.2% of microvesicles having mitochondria based on the total number of extracellular vesicles. That is, more than 0.2% of the extracellular vesicles are microvesicles having mitochondria.
[0023] Preferably, the amount of the factor that promotes mitochondrial production is such that the concentration of the factor in the culture medium is between 0.1 ng / mL and 100,000 ng / mL. Preferably, the amount of the factor that promotes mitochondrial production is such that the concentration of the factor in the culture medium is between 1 ng / mL and 10,000 ng / mL, for example, 10 ng / mL, 50 ng / mL, 100 ng / mL, 500 ng / mL, or 1,000 ng / mL.
[0024] Preferably, the factor promoting mitochondrial production can be selected from the group consisting of hemoglobin oxygenase 1, CoPPIX, heme, heme derivatives such as hemin, heme protein, fragmented red blood cells, mitochondrial structural fragments, cell tissue fragments, and a culture environment with an oxygen concentration of 5%-20%. The oxygen concentration can be 7% to 18%, 10% to 15%, or 12%, 13%, or 14%.
[0025] Preferably, the amount of hemoglobin oxygenase 1 added is such that the concentration of hemoglobin oxygenase 1 in the culture medium is 0.1 ng / mL to 300 ng / mL. Preferably, the amount of hemoglobin oxygenase 1 added is such that the concentration of hemoglobin oxygenase 1 in the culture medium is 1 ng / mL to 100 ng / mL, for example, 10 ng / mL, 30 ng / mL, 50 ng / mL, or 70 ng / mL.
[0026] Preferably, the amount of CoPPIX added is such that the CoPPIX concentration in the culture medium is 0.2 micromoles / kilogram (μmol / kg) to 100 μmol / kg. Preferably, the amount of CoPPIX added is such that the CoPPIX concentration in the culture medium is 1 μmol / kg to 70 μmol / kg, for example, 5 μmol / kg, 10 μmol / kg, 30 μmol / kg, or 50 μmol / kg.
[0027] Preferably, the amount of heme or the heme derivative added is such that the concentration of heme or the heme derivative in the culture medium is 0.2 μmol / kg to 100 μmol / kg. Preferably, the amount of heme or the heme derivative added is such that the concentration of heme or the heme derivative in the culture medium is 1 μmol / kg to 80 μmol / kg, for example, 10 μmol / kg, 20 μmol / kg, 50 μmol / kg, or 70 μmol / kg.
[0028] Preferably, the amount of the factor promoting extracellular vesicle production is such that the concentration of the factor promoting extracellular vesicle production in the culture medium is 10 -7 Preferably, the amount of the factor that promotes extracellular vesicle production is such that the concentration of the factor that promotes extracellular vesicle production in the culture medium is 10 -5 mM to 500 mM, for example, 10 -4 mM, 10 -2 mM, 1 mM, 10 mM, 50 mM, 100 mM or 300 mM.
[0029] Preferably, the factor promoting extracellular vesicle production can be selected from the group consisting of ethanol, EP4 receptor antagonists, such as GW627368X, endosomal protein sorting and transport complex, ARRDC1, tumor suppressor genes related to proteins, and cytochalasin B. The factor promoting extracellular vesicle production can promote the production of microvesicles and exosomes in cells.
[0030] Preferably, the amount of ethanol added is such that the ethanol concentration in the culture medium is 10 mM to 100 mM. More preferably, the amount of ethanol added is such that the ethanol concentration in the culture medium is 20 mM to 70 mM, for example, 30 mM, 40 mM, 50 mM or 60 mM.
[0031] Preferably, the EP4 receptor antagonist is added in an amount such that the concentration of the EP4 receptor antagonist in the culture medium is 0.2 micrograms / milliliter (μg / mL) to 500 μg / mL. Preferably, the EP4 receptor antagonist is added in an amount such that the concentration of the EP4 receptor antagonist in the culture medium is 1 μg / mL to 200 μg / mL, for example, 10 μg / mL, 50 μg / mL, 70 μg / mL, 100 μg / mL, or 150 μg / mL.
[0032] Preferably, the amount of the endosomal protein sorting and transport complex added is such that the concentration of the endosomal protein sorting and transport complex in the culture medium is 0.2 nanomoles per liter (nM) to 500 nM. Preferably, the amount of the endosomal protein sorting and transport complex added is such that the concentration of the endosomal protein sorting and transport complex in the culture medium is 1 nM to 300 nM, for example, 5 nM, 10 nM, 50 nM or 100 nM.
[0033] Preferably, the amount of ARRDC1 added is such that the concentration of ARRDC1 in the culture medium is 0.3 micromolar per liter (μM) to 600 μM. Preferably, the amount of ARRDC1 added is such that the concentration of ARRDC1 in the culture medium is 1 μM to 300 μM, for example, 10 μM, 50 μM or 150 μM.
[0034] Preferably, the amount of the tumor suppressor gene of the related protein added is such that the concentration of the tumor suppressor gene of the related protein in the culture medium is 10 -10 Mole per liter (M) to 10 -6 M. Preferably, the amount of the tumor suppressor gene of the related protein added is such that the concentration of the tumor suppressor gene of the related protein in the culture medium is 10 -9 M to 10 -7 M, for example, can be 10 -8 M.
[0035] Preferably, the amount of cytochalasin B added is such that the concentration of cytochalasin B in the culture medium is 10 -7 M to 10 -4 Preferably, the amount of cytochalasin B added is such that the concentration of cytochalasin B in the culture medium is 10 -6 M to 10 -5 M.
[0036] According to the present invention, in the above-mentioned method for producing an extracellular vesicle composition enriched with microvesicles containing mitochondria, the culture conditions of cells containing mitochondria can be adjusted as needed by those skilled in the art.
[0037] Preferably, the co-cultivation is carried out at 5% carbon dioxide and 35° C. to 39° C. for 60 to 80 hours, preferably 70 to 75 hours.
[0038] To achieve the aforementioned objectives, the present invention further provides an isolated extracellular vesicle composition, wherein the isolated extracellular vesicle composition comprises at least 0.2% of microvesicles having mitochondria based on the total number of extracellular vesicles.
[0039] The isolated extracellular vesicle composition further comprises microvesicles and exosomes. Extracellular vesicles that can encapsulate mitochondria are microvesicles. Combining microvesicles containing mitochondria with other microvesicles or exosomes can enhance their therapeutic efficacy.
[0040] Preferably, the isolated extracellular vesicle composition comprises at least 0.5%, 1%, 2%, or 3% of microvesicles having mitochondria, based on the total number of extracellular vesicles. More preferably, the isolated extracellular vesicle composition comprises at least 4% of microvesicles having mitochondria, for example, at least 4.2%, 4.4%, 4.6%, or 4.8%, based on the total number of extracellular vesicles.
[0041] The present invention further provides a pharmaceutical composition comprising the aforementioned isolated extracellular vesicle composition containing microvesicles having mitochondria, and a pharmaceutically acceptable carrier.
[0042] The present invention further provides a use of an isolated extracellular vesicle composition for preparing a drug for treating or alleviating diabetes. The drug comprises an effective dose of the isolated extracellular vesicle composition and a pharmaceutically acceptable carrier, and the isolated extracellular vesicle composition contains more than 0.2% of microvesicles having mitochondria, based on the total number of extracellular vesicles.
[0043] Preferably, the diabetes is type 2 diabetes.
[0044] The effective dose of the present invention refers to an amount effective in achieving the desired treatment or alleviation of diabetes in terms of dosage and for the required time period; according to the present invention, administration of an isolated extracellular vesicle composition within a specific range of amounts can reduce the fasting blood glucose level and / or insulin concentration of diabetic rats, thereby improving insulin resistance.
[0045] Preferably, the drug is administered to a warm-blooded animal or a human. Preferably, the warm-blooded animal is a mammal or a bird, and the mammal can be a rat or a mouse.
[0046] The present invention further provides a use of an isolated extracellular vesicle composition containing mitochondria, which is used as a drug for treating or alleviating kidney damage. The drug comprises an effective dose of the isolated extracellular vesicle composition and a pharmaceutically acceptable carrier, and the isolated extracellular vesicle composition, based on the total number of extracellular vesicles, contains more than 0.2% microvesicles containing mitochondria.
[0047] The effective dose described in the present invention refers to an amount that is effective in achieving the desired treatment or alleviation of chronic kidney disease in terms of dosage and for the required time period; according to the present invention, it means that by administering a specific range of amounts of an isolated mitochondrial-containing extracellular vesicle composition, the blood creatinine and urea nitrogen levels of chronic kidney disease mice can be reduced.
[0048] Preferably, the kidney injury may be chronic kidney disease or acute kidney injury.
[0049] Preferably, the drug is administered to a warm-blooded animal or a human. Preferably, the warm-blooded animal is a mammal or a bird, and the mammal can be a rat or a mouse.
[0050] The "pharmaceutical composition or drug" described in the present invention can exist in various forms, including, but not limited to, liquid, semi-solid and solid dosage forms, such as solution, emulsion, suspension and other dosage forms similar to or suitable for the present invention.
[0051] In one embodiment, the pharmaceutical composition of the present invention is in the form of an injection, and the injection is administered intravenously.
[0052] The advantages of the present invention include simple, large-scale, continuous production of mitochondrial preparations. Furthermore, microvesicles containing mitochondria can be directly isolated from culture medium, eliminating the need for disrupting cells to extract mitochondria and the costly and time-consuming high-speed centrifugation of mitochondria, thus saving both cost and time. Furthermore, the collected mitochondria are already encapsulated in microvesicles and protected by the small RNA molecules of exocytic factors, making them easier to store in cryopreservation.
[0053] The isolated extracellular vesicle composition of the present invention can indeed reduce fasting blood glucose and / or insulin concentrations in diabetic rats, thereby improving insulin resistance and effectively treating or alleviating diabetes. It can also reduce creatinine and blood urea nitrogen in mice with chronic kidney disease, effectively treating or alleviating kidney damage. BRIEF DESCRIPTION OF THE DRAWINGS
[0054] FIG1 shows the number of mitochondria in extracellular vesicles produced by human mesenchymal stem cells after treatment with factors promoting mitochondrial production, factors promoting extracellular vesicle production, or a combination thereof. * indicates a confidence interval >95%;
[0055] FIG2 shows the ratio of microvesicles with mitochondria produced by human mesenchymal stem cells to the extracellular vesicles produced in each treatment group after treatment with factors promoting mitochondrial production, factors promoting extracellular vesicle production, or a combination thereof. * indicates a confidence interval >95%;
[0056] FIG3 shows the effects of mitochondrial production-promoting extracellular vesicles, the extracellular vesicle production-promoting extracellular vesicles group, and the co-treatment of extracellular vesicles on reducing fasting blood glucose levels in type 2 diabetic rats, * indicates a confidence interval >95%;
[0057] FIG4 shows the effects of mitochondrial production-promoting factor extracellular vesicles, the mitochondrial production-promoting factor extracellular vesicles group, and the co-treatment of extracellular vesicles on reducing fasting insulin concentration in type 2 diabetic rats, * indicates a confidence interval > 95%, ** indicates a confidence interval > 90%;
[0058] FIG5 shows the effects of mitochondrial production-promoting extracellular vesicles, the extracellular vesicle production-promoting extracellular vesicles group, and the co-treatment of extracellular vesicles on reducing blood creatinine in chronic kidney disease mice, * indicates a confidence interval >95%;
[0059] FIG6 shows the effects of mitochondrial production-promoting extracellular vesicles, the extracellular vesicle production-promoting extracellular vesicle group, and co-treatment of extracellular vesicles on reducing blood urea nitrogen in chronic kidney disease mice. * indicates a confidence interval >95%. DETAILED DESCRIPTION
[0060] The present invention will be further illustrated by the following examples, which are not intended to limit the present invention disclosed above. Those skilled in the art of the present invention may make slight improvements and modifications without departing from the scope of the present invention.
[0061] Example 1: Cultivation of Mesenchymal Stem Cells to Generate Extracellular Vesicles (EVs)
[0062] Human mesenchymal stem cells isolated from the umbilical cord of healthy donors were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and high glucose (glucose concentration: 4500 mg / L) in 150 mm culture dishes. The cells were incubated at 37°C in a 5% CO2 atmosphere for 24 to 48 hours until the cells reached 40% to 60% confluence. After rinsing the cells twice with the DMEM supplemented with 10% FBS, the cells were treated with four different methods: a control group in which cells were cultured with culture medium alone without additional treatment; a group in which cells were treated with a mitochondrial growth factor (mitochondrial growth factor) at a concentration of 40 ng / mL. In this example, the mitochondrial growth factor was hemoglobin oxygenase 1 (Enzo LifeSciences, Ann Arbor, MD). Arbor, MI, USA); in the group treated with an extracellular vesicle production-promoting factor, the concentration of the extracellular vesicle production-promoting factor in the culture medium was 50 mM after the addition of the extracellular vesicle production-promoting factor. In this example, ethanol was used as the extracellular vesicle production-promoting factor; or in the group co-treated with a mitochondrial production-promoting factor and an extracellular vesicle production-promoting factor (hereinafter referred to as the co-treatment group), in this example, the mitochondrial production-promoting factor was added first, followed by the extracellular vesicle production-promoting factor. Specifically, after 24 hours of culture, hemoglobin oxygenase 1, a mitochondrial production-promoting factor, was added to the culture medium, bringing the hemoglobin oxygenase 1 concentration to 40 ng / mL. At the 36th hour of culture, ethanol, a factor promoting extracellular vesicle production, was added to the culture medium, bringing the ethanol concentration to 50 mM. After 72 hours of culture, the supernatant was collected to collect extracellular vesicles from the conditioned medium (CM) produced in each treatment group. Specifically, the conditioned medium from each treatment group was centrifuged at 3,000 g for 10 minutes to remove dead cells and large cell fragments. The supernatant from each conditioned medium was then pre-washed using an extracellular vesicle isolation pre-clearing column. The pre-wash supernatant was transferred to a Capturem™ extracellular vesicle isolation column and centrifuged at 1,000 g for 2 to 4 minutes at room temperature. The column was then rinsed once with extracellular vesicle isolation wash buffer, and the extracellular vesicles from each group were eluted using the extracellular vesicle elution buffer provided in the kit.
[0063] Test Example 1: Nanoparticle Tracking Analysis
[0064] Extracellular vesicles (EVs) obtained from each treatment in Example 1 were diluted with phosphate-buffered saline (PBS) to a concentration of 20-100 particles per field of view. The number of mitochondrial-bearing microvesicles was measured using nanoparticle tracking analysis (NTA), and the final count of mitochondrial-bearing microvesicles was performed using fluorescent nanoparticle tracking analysis (fNTA). The EVs isolated from Example 1 were labeled with TMRE (tetramethylrhodamine ethyl ester) fluorescent dye to detect mitochondria within EVs. The excitation and emission wavelengths of TMRE fluorescent dye were 550 nanometers (nm) and 575 nm, respectively. The sizes of EVs and mitochondrial-bearing microvesicles were measured using a nanoparticle size analyzer (NanoSight LM10-HS system, Malvern, UK), and the data were analyzed using Nanoparticle Tracking Software (version 2.3).
[0065] The results of mitochondrial number measurement for each treatment group are shown in Figure 1. It can be seen that the mitochondria-producing factor-treated group, the extracellular vesicle production-promoting factor-treated group, and the co-treatment group all produced more mitochondria-containing microvesicles than the control group. Therefore, treatment of human mesenchymal stem cells with the mitochondria-producing factor, the extracellular vesicle production-promoting factor, or the co-treatment of the mitochondria-producing factor and the extracellular vesicle production-promoting factor all promoted the production of more mitochondria-containing microvesicles. In particular, the mitochondria-producing factor-treated group and the co-treatment group were able to promote the production of more mitochondria-containing microvesicles by human mesenchymal stem cells, with the numbers being 16 and 132 times greater than those in the control group, respectively.
[0066] Furthermore, the results in Figure 2 were divided by the number of extracellular vesicles produced in each treatment group to obtain the proportion of microvesicles containing mitochondria in the total extracellular vesicles produced in each treatment group. As shown in Figure 2, compared to the control group, the extracellular vesicle production-promoting factor group, the extracellular vesicle production-promoting factor group, and the co-treatment group showed a higher proportion of extracellular vesicles containing mitochondria. Therefore, treatment of human mesenchymal stem cells with a mitochondrial production-promoting factor, an extracellular vesicle production-promoting factor, or a combination of a mitochondrial production-promoting factor and an extracellular vesicle production-promoting factor all resulted in a higher proportion of extracellular vesicles containing mitochondria in human mesenchymal stem cells. In particular, the mitochondrial production-promoting factor group and the co-treatment group showed a higher proportion of extracellular vesicles containing mitochondria in the extracellular vesicles produced by human mesenchymal stem cells, at 1.89% and 4.9%, respectively, representing 14.44-fold and 37.40-fold increases, respectively, compared to the control group.
[0067] Therefore, the combined use of factors promoting mitochondria production and factors promoting extracellular vesicle production can indeed promote cells with mitochondria to produce microvesicles with mitochondria, and the method of the present invention can indeed produce a large number of microvesicles with mitochondria.
[0068] Test Example 2 Animal Experiment on Type II Diabetes Rat Model
[0069] Male albino rats weighing 150-200 grams (g) were housed in cages of seven and housed in a controlled environment (22°C to 25°C) with a 12-hour light-dark cycle (lights on from 08:00 to 20:00). Animals had free access to food and water. On day 0, the animals were randomly divided into two groups: a normal control group (n=7) fed a standard laboratory chow diet for two weeks and a diabetic group fed a high-fat diet (HFD; 20% protein, 60% fat, and 20% carbohydrates) for two weeks. On day 14, the diabetic group received an intraperitoneal injection of 45 mg / kg of low-dose streptozotocin (STZ) to induce type 2 diabetes. Low-dose STZ and a high-fat diet are essential for inducing insulin resistance in type 2 diabetes. Therefore, all rats had free access to group-specific food and water until the end of the experiment. On day 21 of the experiment, fasting blood glucose (FBG) and insulin levels were measured in the control group and the diabetic group after overnight fasting. The type 2 diabetes model rats were further divided into: a diabetic control group (control group), a group containing extracellular vesicles that promote mitochondrial production factors, a group containing extracellular vesicles that promote extracellular vesicle production factors, and a co-treated extracellular vesicle group (n = 7 per group). Each group of rats was injected with PBS buffer solution (diabetic control group) twice a week for a total of 2 weeks; or injected with the extracellular vesicles obtained in Example 1 twice a week, wherein each injection was 3×10 per kg body weight. 8 During the experiment, all rats were fed with normal diet, and blood was collected from the rats three weeks after administration.
[0070] Figures 3 and 4 show the improvements in fasting blood glucose and insulin resistance in diabetic rats following various treatments. Figure 3 shows that fasting blood glucose levels in diabetic rats in all treatment groups—the mitochondrial production-promoting extracellular vesicles group, the mitochondrial production-promoting extracellular vesicles group, and the co-treatment extracellular vesicles group—were lower than those in the diabetic control group. The mitochondrial production-promoting extracellular vesicles group and the co-treatment extracellular vesicles group showed the greatest effects. The mitochondrial production-promoting extracellular vesicles group reduced fasting blood glucose by 61.78% compared to the diabetic control group, while the co-treatment extracellular vesicles group reduced fasting blood glucose by 65.35% compared to the diabetic control group, achieving values similar to those in the normal control group.
[0071] As can be seen in Figure 4, the fasting insulin concentrations of diabetic rats in all treatment groups: the mitochondrial production factor-promoting extracellular vesicles group, the extracellular vesicles group and the co-treated extracellular vesicles group were lower than those in the diabetic control group. Among them, the mitochondrial production factor-promoting extracellular vesicles group and the co-treated extracellular vesicles group had the best effects. The mitochondrial production factor-promoting extracellular vesicles group reduced the fasting insulin concentration by 53.70% compared with the diabetic control group, and the co-treated extracellular vesicles group reduced the fasting insulin concentration by 56% compared with the diabetic control group, and were similar to those of the normal control group rats.
[0072] Therefore, the microvesicles and extracellular vesicle compositions with mitochondria prepared by the method of the present invention can indeed treat type 2 diabetes, reduce fasting blood sugar levels, and improve high insulin concentrations caused by insulin resistance in diabetic rats.
[0073] Test Example 3 Animal Experiment on Chronic Kidney Disease Mouse Model
[0074] All animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals. Six-week-old BALB / c mice were housed in a temperature-controlled environment (25°C) with a 12-hour light-dark cycle. The mice were divided into the following five groups (n=5 per group): (1) normal control group, (2) chronic kidney disease control group (treated with PBS), (3) group containing extracellular vesicles that promote mitochondrial production factors, (4) group containing extracellular vesicles that promote extracellular vesicle production factors, and (5) group containing co-treated extracellular vesicles. Chronic kidney disease in mice was induced by feeding them with 0.25% adenine-containing feed. One week later, each group of mice was injected with PBS buffer solution (chronic kidney disease control group) twice a week; or injected with the extracellular vesicles obtained in each treatment group in Example 1 twice a week, wherein 3×10 per kg body weight was administered each time. 8 During the experiment, all mice were fed with normal diet, and blood was collected from the mice three weeks after administration.
[0075] The collected mouse blood was centrifuged at 1500 rpm for 30 minutes, and the upper serum layer was collected and used to measure blood creatinine and blood urea nitrogen (BUN) levels using an enzyme-linked immunosorbent assay (ELISA). The absorbance at 450 nm was measured using a microplate reader (Thermo Fisher Scientific).
[0076] Figures 5 and 6 show the improvements in blood creatinine and urea nitrogen levels in CKD mice following various treatments. Figure 5 shows that all treatment groups—the mitochondrial production-promoting extracellular vesicles group, the mitochondrial production-promoting extracellular vesicles group, and the co-treatment extracellular vesicles group—had lower blood creatinine levels compared to the CKD control group. The mitochondrial production-promoting extracellular vesicles group and the co-treatment extracellular vesicles group showed the greatest effects. The mitochondrial production-promoting extracellular vesicles group reduced creatinine levels by approximately 54.06% compared to the CKD control group, while the co-treatment extracellular vesicles group reduced creatinine levels by 67.96% compared to the CKD control group, and these levels were similar to those in the normal control group.
[0077] Figure 6 shows that blood urea nitrogen levels in CKD mice in all treatment groups—the mitochondrial production-promoting extracellular vesicles group, the mitochondrial production-promoting extracellular vesicles group, and the co-treatment extracellular vesicles group—were lower than those in the CKD control group. The mitochondrial production-promoting extracellular vesicles group and the co-treatment extracellular vesicles group showed the greatest effects. The mitochondrial production-promoting extracellular vesicles group reduced urea nitrogen levels by approximately 66.80% compared to the CKD control group, while the co-treatment extracellular vesicles group reduced urea nitrogen levels by an even greater 79.42% compared to the CKD control group, achieving values similar to those in the normal control group.
[0078] Therefore, the microvesicles with mitochondria prepared by the method of the present invention can indeed treat and improve diabetes; and can reduce the creatinine value and urea nitrogen value in the blood of mice with renal damage and chronic kidney disease.
[0079] In summary, the present method can indeed produce large quantities of microvesicles containing mitochondria. Furthermore, the isolated extracellular vesicle composition produced by the present method, containing a large number of microvesicles containing mitochondria, can indeed treat or alleviate diabetes, such as type 2 diabetes, and kidney damage, such as chronic kidney disease.
[0080] The above description is only for the convenience of explaining a preferred embodiment of the present invention and is not intended to limit the scope of the present invention. The scope of rights claimed by the present invention should be based on the scope of the patent application.
Claims
1. A use of a combined use of a factor promoting mitochondrial production and a factor promoting extracellular vesicle production, which is used to promote cells having mitochondria to generate microvesicles having mitochondria.
2. The use of the combined use of a factor promoting mitochondrial production and a factor promoting extracellular vesicle production according to claim 1, wherein: The factor promoting mitochondrial production can be selected from the group consisting of: hemoglobin oxygenase 1, CoPPIX, heme, heme derivatives, mitochondrial structure fragments, cell tissue fragments and 5%-20% oxygen concentration environment culture.
3. The use of the combined use of a factor promoting mitochondrial production and a factor promoting extracellular vesicle production according to claim 1, wherein: The factor promoting the production of extracellular vesicles can be selected from the group consisting of ethanol, EP4 receptor antagonist, endosomal protein sorting and transport complex, ARRDC1, tumor suppressor gene of related protein and cytochalasin B.
4. The use of the combined use of a factor promoting mitochondrial production and a factor promoting extracellular vesicle production according to claim 1, wherein: The cells having mitochondria are mesenchymal stem cells, hematopoietic stem cells, bone marrow stem cells or liver cells.
5. A method for producing an extracellular vesicle composition enriched in microvesicles having mitochondria, comprising: Step (1) provides a cell having mitochondria; and Step (2) adds a factor promoting mitochondrial production and a factor promoting extracellular vesicle production to the cells having mitochondria and co-cultivates them in a culture medium to obtain an extracellular vesicle composition rich in microvesicles having mitochondria, wherein the extracellular vesicle composition rich in microvesicles having mitochondria has more than 0.2% of microvesicles having mitochondria based on the total number of extracellular vesicles.
6. The method for producing an extracellular vesicle composition rich in microvesicles having mitochondria according to claim 5, wherein: The amount of the factor promoting mitochondrial production added is such that the concentration of the factor promoting mitochondrial production in the culture medium is 0.1 ng / mL to 100000 ng / mL.
7. The method for producing an extracellular vesicle composition rich in microvesicles having mitochondria according to claim 5 or 6, wherein: The amount of the factor promoting the production of extracellular vesicles added is such that the concentration of the factor promoting the production of extracellular vesicles in the culture medium is 10-7 millimoles per liter (mM) to 800 mM.
8. An isolated extracellular vesicle composition, comprising 0.2% or more of microvesicles having mitochondria based on the total number of extracellular vesicles.
9. The isolated extracellular vesicle composition according to claim 8, wherein the isolated extracellular vesicle composition is prepared by the method according to any one of claims 5 to 7 and then isolated. 10 . A pharmaceutical composition comprising the isolated extracellular vesicle composition according to claim 8 or 9 , and a pharmaceutically acceptable carrier.
11. Use of an isolated extracellular vesicle composition for preparing a drug for treating or alleviating diabetes, wherein: The medicine comprises an effective dose of an isolated extracellular vesicle composition and a pharmaceutically acceptable carrier, and the isolated extracellular vesicle composition has more than 0.2% of microvesicles with mitochondria based on the total number of extracellular vesicles.
12. Use of the isolated extracellular vesicle composition according to claim 11, wherein: The diabetes is type 2 diabetes.
13. Use of the isolated extracellular vesicle composition according to claim 11 or 12, wherein: The drug is administered to warm-blooded animals or humans.
14. Use of an isolated extracellular vesicle composition for preparing a drug for treating or alleviating kidney damage, wherein: The medicine comprises an effective dose of an isolated extracellular vesicle composition and a pharmaceutically acceptable carrier, and the isolated extracellular vesicle composition has more than 0.2% of microvesicles with mitochondria based on the total number of extracellular vesicles.
15. Use of the isolated extracellular vesicle composition according to claim 14, wherein: The kidney damage is chronic kidney disease.
16. Use of the isolated extracellular vesicle composition according to claim 14 or 15, wherein: The drug is administered to warm-blooded animals or humans.
Citation Information
Patent Citations
Method for promoting generation and secretion of extracellular vesicae of mesenchymal stem cells
CN107629999A
Application of heme and analogues thereof in preparation of medicine for treating mitochondrial diseases
CN113813371A
Isolated mitochondria with smaller size and lipid membrane-based vesicles wrapping isolated mitochondria
CN114901258A
Repair-promoting microvesicles based on denucleated stem cells as well as preparation method and application of repair-promoting microvesicles
CN115537386A
